Pulse Biosciences (PLSE) EBITDA (2021 - 2025)
Historic EBITDA for Pulse Biosciences (PLSE) over the last 5 years, with Q3 2025 value amounting to -$19.4 million.
- Pulse Biosciences' EBITDA fell 5287.85% to -$19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.7 million, marking a year-over-year decrease of 6199.47%. This contributed to the annual value of -$53.6 million for FY2024, which is 2694.86% down from last year.
- As of Q3 2025, Pulse Biosciences' EBITDA stood at -$19.4 million, which was down 5287.85% from -$19.2 million recorded in Q2 2025.
- In the past 5 years, Pulse Biosciences' EBITDA ranged from a high of -$9.2 million in Q4 2022 and a low of -$19.4 million during Q4 2024
- In the last 5 years, Pulse Biosciences' EBITDA had a median value of -$14.3 million in 2021 and averaged -$14.4 million.
- Its EBITDA has fluctuated over the past 5 years, first surged by 4325.83% in 2023, then tumbled by 6839.15% in 2025.
- Quarter analysis of 5 years shows Pulse Biosciences' EBITDA stood at -$15.4 million in 2021, then skyrocketed by 40.34% to -$9.2 million in 2022, then fell by 29.75% to -$11.9 million in 2023, then tumbled by 62.45% to -$19.4 million in 2024, then changed by 0.0% to -$19.4 million in 2025.
- Its EBITDA was -$19.4 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$16.8 million in Q1 2025.